Mike Lam

Cooley advised the underwriters in Vistagen Therapeutics’ $100 million follow-on offering of common stock, pre-funded warrants, and two tranches of common stock warrants, with Jefferies, Stifel and William Blair acting as lead book-running managers. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders. Partners Denny Won, Charlie Kim and Courtney Tygesson led the Cooley team.

Cooley advised the underwriters in the upsized initial public offering of Sagimet Biosciences, a clinical-stage biotechnology company, at $85 million.

Cooley advised the underwriters in the upsized $345.1 million initial public offering of Apogee Therapeutics, a biotechnology company.

Cooley advised the underwriters in IGM Biosciences’ $97.5 million public offering of 9,000,000 shares of non-voting common stock and 3,187,500 shares of voting common stock, each at the public offering price of $8.00 per share, as well as a $22.5 million concurrent private placement. IGM is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, autoimmune and inflammatory diseases, and infectious diseases. Denny Won, Kristin VanderPas and Charlie Kim led the Cooley team.

Cooley advised the underwriters in Erasca’s $100 million follow-on offering of 15,384,616 shares of common stock at a public offering price of $6.50 per share. Erasca is a clinical-stage biopharmaceutical company discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Partners Charlie Kim, Kristin VanderPas and Denny Won led the Cooley team.